Willow Biosciences Inc
TSX:WLLW

Watchlist Manager
Willow Biosciences Inc Logo
Willow Biosciences Inc
TSX:WLLW
Watchlist
Price: 0.17 CAD Market Closed
Market Cap: 107m CAD

EV/EBIT
Enterprise Value to EBIT

-34.2
Current
-23.2
Median
6.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-34.2
=
Enterprise Value
107.5m CAD
/
EBIT
-3.1m CAD
All Countries
Close
EBIT Growth EV/EBIT to Growth
CA
Willow Biosciences Inc
TSX:WLLW
Average EV/EBIT: 46.4
Negative Multiple: -34.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.6
N/A N/A
NL
argenx SE
XBRU:ARGX
60.4
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A